Croda Pharma ’s Post

💊Tow major trends transform the landscape of peptide therapeutics dramatically 👇🏽👇🏽👇🏽 ⭐ Chemical or display screening platforms become state-of-the-art for target-based drug development, resulting in a significantly enriched preclinical pipeline. ⭐ The success of GLP-1 analogs for weight loss and obesity treatment is moon-shooting the pharmaceutical relevance of peptides, causing a shortage of external synthesis capacity. 👉🏽 The performance of novel drug development projects hinges on a seamless transition from screening to the clinics. A critical component is the synthetic in-house capability to rapidly scale up and improve peptide quality in parallel, along with the ability to adopt complex chemistry to advance the stability and efficacy of your lead compounds. ⏳ The clock is ticking. It's crucial to equip ourselves with the right manufacturing tools to stay ahead of the curve in peptide therapeutics. 💡 We value your insights and invite you to join us at #Tides2024 at booth #419. Let's explore how our PurePep solutions can elevate your peptide projects together. 📅 We invite you to learn more about us and book a meeting now! https://lnkd.in/dH4BnMwJ

Innovative strategies for maximising binding capacity As the demand for mRNA-based therapies surges, the efficiency of the production process becomes paramount. Binding conditions in affinity chromatography need to be optimised, to keep up with the increasing efficiency of IVT reactions, and to deliver high yields and purities. In this application note, we demonstrate that multi-parallel approaches, such as screening in 96-well plate format, can significantly cut the development time by enabling the examination of multiple conditions simultaneously. In this application note, we show: - Innovative strategies for maximising the dynamic binding capacity of Oligo dT - How multi-parallel approaches significantly cut the development time by testing numerous conditions in parallel - Insightful analysis of the critical factors influencing binding efficiency - Guidance on transitioning/scalability to larger chromatographic columns for industrial applications Download now to access the application note and elevate your drug development strategies to new heights. https://lnkd.in/eqQ5H-Cy Brought to you by Sartorius BIA Separations Inc. #mRNA #DrugDiscovery #LifeSciences

At Biofortuna, we are committed to helping our Customers extend the accessibility and accuracy of near patient diagnostics. One example of this is through the development and commercial scale manufacture of customised Lyo beads. 🔬 Why choose Lyo beads? 🔬 ✅Extended shelf life and enhanced stability: Lyo beads ensure long-term stability and potency of reagents, enzymes and antibodies, guaranteeing consistent performance and reproducibility. ✅ Convenient and ready-to-use: Pre-formatted beads eliminate the need for preparation time, streamlining your workflow and increasing efficiency. ✅ Precise dosing: Each Lyo bead contains an exact amount of reagent, providing accurate and reproducible results every time. ✅ Reduced contamination risk: Individually packaged beads minimise the chance of cross-contamination, maintaining the integrity of your samples. ✅ Quick reconstitution: Lyo beads reconstitute rapidly and effortlessly, saving valuable preparation time in the lab. Whether you're working in diagnostics, life sciences research, or pharmaceutical development, Lyo beads are designed to support your critical work with unmatched reliability and convenience. 👉 Learn more https://lnkd.in/edwPg3gf

It's crucial to clearly understand the molecule and it's solid-state properties to guide the appropriate formulation development pathway for First-in-Human. Correct formulation development strategy minimizes the requirement for multiple prototype formulations, PK bridging studies and can accelerate the drug development in the fastest, cost effective and the most material-sparing manner. #DrugDevelopment #CMC #Formulation #FormulationDevelopment #ResearchandDevelopment #SolidState #API #DrugSubstance #DrugProduct #Manufacturing #CTM #CRO #CDMO

The Charge Variant Reconstruction workflow in Byos enables users to correlate cIEF traces with peptide mapping data, helping to identify species that are not represented in the cIEF trace and providing deeper insights into charge heterogeneity. This workflow searches for PTMs that alter the protein's pI and constructs a theoretical cIEF trace, which is then overlaid onto the experimental trace for comparison. Curious to see how this is applied in real-world scenarios? Make sure to register for this week’s webinar 🤔 👇

Pharma Applications in X-ray Powder Diffraction

Utilizing hot-stage polarized microscopy and ATR-FTIR for ramipril co-crystal screening, supported by principal component analysis and cluster analysis. https://ow.ly/m8xz50Qx2zK #PharmaceuticalTechnology #Pharmacy #DrugQuality

📣REMINDER!📣 Dose Number as a Tool to Guide Lead Optimization of Orally Bioavailable Compounds | https://lnkd.in/gz6gaadu   Thu, Oct 10, 2024  8 AM PDT / 11 AM EDT / 5 PM CEST Do you want to learn more about ways to improve solubility-limited absorption and why dose number is an important tool to guide a lead optimization? In this Flask Talk, leading scientists from Merck, Peter Wuelfing and Abdellatif ElMarrouni, will present a strategy to improve oral bioavailability. Dose number is a simplified metric to predict the absorption of a compound based on solubility at an expected clinical dose. It serves as a tool for Medicinal Chemists to rapidly profile and improve molecules during a drug discovery campaign. The dose number is also a valuable parameter to define a clinical candidate. Peter and Abdellatif will present the background of the dose number equation and share how it can be effectively used during a discovery campaign. Don't miss this talk to ask any question on this valuable parameter and learn how you could use it more effectively on your discovery campaign. Register here: https://lnkd.in/gz6gaadu

🔍Explore Biopharma Group's new case study on freeze drying of ADCs 🔍 This case study highlights how Biopharma Groups team of specialist scientists successfully transitioned a drug product from a liquid into a freeze dried format which avoiding compromising on quality. If you would like to discuss this case study in more detail or have an ADC project of your own that you require support with then please get in touch: https://bit.ly/3H9yivP #ADCs #casestudy #adccasestudy #freezedrying #liquidintopowder #lyophilisation #lyophilization #antibodies #BiopharmaGroup

Bringing a lab scale lipid nanoparticle (#LNP) formulation to large scale is not just a simple scale-up of volume, time, and equipment. It may indeed be a complex process with many potential challenges and hurdles for formulators. Reason enough to spend a bit more time on it, we thought. That's why we invited our #drugdelivery experts Alex Leung and Michael Parr from Evonik's Vancouver site to share their experience with us during last week's live #webinar on large scale #lipidnanoparticle formulations. It was really interesting to hear how complex the topic can be, and the many questions from our audience confirmed: This is definitely a topic worth discussing. If you missed the session and think it could be of value for you and your colleagues, the recording of the event is now available as on-demand webinar on our online platform #onCare. Register now at https://lnkd.in/eQdX2aXc and profit from further value-adding tools and ressources around our product and service portfolio. #lipids #parenteral #rna #mrna #injectables #implants #cmo #cdmo #contractmanufacturing #outsourcing #biopharma #pharma #healthcare #webcast